IngredientsGallotannin, or common tannic acid, is the best known of the hydrolyzable tannins. It is a type of hydrolysable tannin that consists of a sugar molecule substituted with galloyl groups, and it is a complex polyphenolic organic structure that yields gallic acid and either glucose or quinic acid as hydrolysis products.
Gallotannins are important hydrolysable tannins constituting of at least one galloyl moiety and one sugar/cyclitol molecule, such as glucose and quinic acid. Tannins can be classified into hydrolyzable and nonhydrolyzable (condensed) tannins. Hydrolyzable tannins possess a polyhydric alcohol group in the center and hydroxyl groups that are esterified by gallic acid or hexahydroxydiphenic acid, called gallotannins and ellagitannins, respectively. Gallotannins are formed by the esterification of D-glucose hydroxyl groups with gallic acid; the gallolyl moieties are bound by a depside bond.
Structurally surrounded by several galloyl units, gallotannins have a polyol as the core, most often glucose; on the other hand, gallotannins are identified as polygalloyl esters of glucose. The compounds can have 3 to 12 galloyl residues but may be further oxidatively crosslinked and complex.
The most commercially and pharmacologically prominent gallotannin is 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG, or pentagalloylglucose). Penta-O-galloyl-D-glucose, also known as pentagalloyl glucose (PGG), is classified as a gallotannin; it is a hydrolyzable tannin abundant in many plants, including Rhus chinensis, Paeonia suffruticosa, Bouea macrophylla, and Toona sinensis. The naturally occurring polyphenolic compound PGG exists in beta-PGG form, whereas an anomeric alpha-PGG is rarely found in nature. 1,2,3,4,6-Penta-O-Galloyl-β-D-Glucose (PGG) is a hydrolysable tannin that belongs to the group of gallotannins but also participates in the formation of ellagitannins. PGG is composed of five galloyl groups with a glucose at its core and has structural characteristics that confer a high biological power.
PGG is the common and immediate precursor of the two classes of hydrolyzable tannins, gallotannin and ellagitannin.
The term "gallotannin" also broadly refers to the commercial tannin mixture commonly known as tannic acid, assigned CAS number 1401-55-4, with a reported molecular formula of C76H52O46 and a molecular weight of approximately 1701.20 g/mol in its pentagalloylglucose-based form.
Gallotannin is produced by extraction with water or organic solvents from the galls of certain trees, notably the Aleppo oak (Quercus infectoria) and Chinese nutgall (Rhus chinensis).
Various galloyl-glucopyranoses occur naturally in many plants. Representatively, the occurrence of gallotannins was found in the extracts of Chinese galls (Rhus semialata) and Turkish galls (Gallae turcicea). Also, the presence of gallotannins in plants such as Paeonia and Schinus terebinthifolius, the leaves of Sicilian sumac (Rhus coriaria L.) and the common smoke tree (Cotinus coggygria Scop.) were at sufficient levels to allow direct isolation and utilization.
Pentagalloylglucose can be found in Punica granatum (pomegranate), Elaeocarpus sylvestris, Rhus typhina (Staghorn sumac), Paeonia suffruticosa (Tree Peony), Mangifera indica (mango), and Bouea macrophylla Griffith (maprang).
Gallotannins are widely distributed in plant-based foods and medicinal plants, such as Pistacia lentiscus L., Chinese rose (Rosa chinensis), toon (Toona sinensis), Chinese gall (Galla chinensis), mango (Mangifera indica L.), and sumac (Rhus coriaria L.).
The maple (Acer) genus is a reported source of bioactive (poly)phenols, including gallotannins. Among 42 edible beans, red sword bean (Canavalia gladiata) was found to have the highest content of gallotannins. The first report of the presence of gallotannins in the nutshell of camellia tree (Camellia oleifera C. Abel) was also disclosed. From the byproducts of mango — barks, kernels, leaves, etc. — gallotannins were identified and quantitated.
Tannins are natural polyphenolic components found in fruits such as grapes, apples, pears, plums, peaches, strawberries, and cranberries as well as in beverages including wine and tea. Other sources of tannins are Acer ginnala Maxim., Caesalpinia spinosa (Molina) Kuntze, Caesalpinia brevifolia Baill., Hamamelis virginiana L., Quercus infectoria Oliv., Terminalia chebula Retz., Eucalyptus sieberiana F. Muell., and Schinopsis Engl. species.
Three plants (or their parts) with maximum PGG content were Rhus chinensis Mill, Bouea macrophylla seed, and Mangifera indica kernel.
The class of gallotannins is structurally diverse. Currently, 31 gallotannins have been isolated and identified from different parts of pomegranate alone, which can be divided into five types according to the number of galloyl groups linked to the glucose residue. Gallotannins contain ester linkage(s) between galloyl group(s) linked to a glucose residue.
The 2,3,4,6-tetra-O-galloyl-D-glucopyranose (TGG) and 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose (β-PGG), found in many plant families, are key intermediates in the biosynthesis of nearly all hydrolyzable plant polyphenols. Beyond PGG, the class includes specific named members such as ginnalin A (found in Acer species) and hamamelitannin (HAM), found in witch hazel. Both of these gallotannins possess two galloyl moieties linked to a core monosaccharide having anti-oxidant, anti-inflammatory, and anti-carcinogenic abilities.
Initially applied in tanned leather, but with the discovery of their antioxidant effect and additional reaction mechanisms, application of gallotannins in food, medicine, feed, cosmetics, and other fields is increasing. Gallotannin is available commercially as:
Gallotannins contribute significantly to taste, flavor, color, and stability, while they could be used in food packaging.
Medicinal plants containing gallotannins, Rhus chinensis Mill. and Terminalia chebula Retz., have been prescribed for the treatment of cough, constipation, dysentery, and dysfunctions of the liver and kidney in traditional Chinese medicine.
Galla Rhois (GR) is the excrescence formed by parasitic aphids, primarily Schlechtendalia chinensis Bell, on the leaf of sumac, Rhus javanica (Anacardiaceae). This compound has been found to have favorable ethnopharmacological properties. Gallotannin-enriched extract isolated from Galla Rhois (GEGR) has traditionally been used for treatment of diarrhea, several skin diseases, seminal emissions, excessive sweating, abscess, bleeding, and chronic cough without any recorded toxicity.
In Korea, Galla Rhois has long been used as a traditional medicine for treatment of diarrhea, seminal emissions, excessive sweating, bleeding, and chronic cough, although there is little scientific evidence supporting these pharmacological claims in the form of controlled human trials.
Rhus chinensis Mill (also known as Rhus semialata Murray, Family Anacardiaceae) is a deciduous underutilized wild edible fruit tree native to China and Japan and distributed in tropical and subtropical regions. Fruits and galls (Galla chinensis) of this tree are utilized in medicine, food, fiber, juice, and ingredients of traditional products. A number of phytoconstituents such as gallotannin, gallic acid, ellagic acid, phenols, flavonoids, organic acids, and minerals isolated from R. chinensis were reported to have various pharmacological activities.
Originally, "tannin" was coined by Seguin to describe the substances present in vegetable extracts. The galls of Quercus infectoria — known historically as Aleppo galls or Turkish galls — have been employed for centuries in the traditional medicine of the Middle East, Persia, and parts of Europe. Quercus infectoria (QI) is an oak tree belonging to the Fagaceae (Quercaceae) family. Bioactive compounds can be found in various parts of the QI plant, including the bark, root, leaf, flower, seed, nut, legume and gall. The main medicinal benefit of the QI plant lies in its gall, which is an excrescence formed due to the stimulus by Adleria gallae-tinctoriae gall-wasp egg deposition. In Malaysia, the QI galls are commonly known as 'manjakani'.
In nature, tannins have been found in a variety of plants, fruits, wines, forages, and tea. The use of oak-bark and gallnut-derived preparations was widespread in European folk medicine for their astringent effects. Decoctions and infusions were prepared from dried galls and bark and used internally and topically. The astringent property of gallotannins — their ability to precipitate proteins and contract tissues — was the primary mechanistic rationale recognized even before modern chemistry.
Due to the precipitation with proteins, tannins were introduced to leather tanning initially. This industrial use was the basis of the word "tanning." In parallel, the same protein-precipitating action was employed medicinally: topical application of gallnut extracts was used to treat wounds and burns, exploiting the compound's ability to form a protective, astringent film on damaged skin. Gallnut is also widely used in medicine, the chemical industry, mining and metallurgy, agriculture, food, the light industry, electronics, and other industries.
PGG is synthesized from gallic acid and glucose by a series of strictly position-specific galloylation steps. Esterification of gallic acid and glucose to yield β-glucogallin (1-O-galloyl-β-D-glucose) is the first enzyme-catalyzed reaction using UDP-glucose as activated substrate. Further substitution of glucose hydroxyls is not randomly distributed in these conversions but displays an unexpected extreme specificity, thus constituting the metabolic sequence β-glucogallin → 1,6-digalloylglucose → 1,2,6-trigalloylglucose → 1,2,3,6-tetragalloylglucose and finally 1,2,3,4,6-pentagalloylglucose. In the second step, the galloylation of pentagalloylglucose continues to yield hexa-, hepta-, octa-, etc.-galloylglucose derivatives, and to form an esteric link between two galloyl moieties (gallotannins or depsidic metabolites).
Upon oral consumption or in biological systems, gallotannins undergo hydrolysis to release free gallic acid and glucose. Gallic acid is itself a biologically active phenolic acid, and some of the downstream pharmacological effects attributed to gallotannins may be mediated by gallic acid, its metabolites (such as pyrogallol), or the intact parent molecule. The relative contribution of each is not yet fully delineated in human studies.
The high number of phenolic groups in gallotannins, such as PGG, makes them superior antioxidants. PGG is one of the most potent antioxidants in tannins. Gallotannin induces Cox-2 (cyclooxygenase-2) expression and is a free radical scavenger.
Tannic acid demonstrated the most potent antioxidative activity (EC50 = 2.84 μM), with potency increasing proportionally to the number of galloyl moieties. This structure-activity relationship is a key finding across multiple studies: the greater the degree of galloylation of the glucose core, the more potent the antioxidant effect.
Antioxidant mechanisms include direct free radical scavenging, chelation of redox-active metal ions such as iron and copper, and inhibition of pro-oxidative enzymes. Quite strong antioxidant effects of gallotannin against H2O2 could also be due to its strong iron chelating effects.
The capacity of gallotannins to bind proteins and enzymes (causing astringency) is a function of the number of galloyl groups and their spatial flexibility, which allows for cross-linking with proteins through multiple hydrogen bonds and hydrophobic interactions. With a large number of hydroxyl or other functional groups located on the skeleton, tannins are capable of forming cross-linkages with proteins and other macromolecules.
Pentagalloylglucose can precipitate proteins, including human salivary α-amylase. This enzyme-inhibitory property extends to digestive enzymes relevant to metabolism. Extensive research demonstrates that gallotannins specifically obstruct α-amylase and pancreatic lipase, enhance insulin sensitivity, modulate short-chain fatty acid production, alleviate oxidative stress, exhibit anti-inflammatory properties, and influence the gut microbiota, collectively contributing to their antidiabetic efficacy.
Gallotannin is an inhibitor of PARG (poly(ADP-ribose) glycohydrolase). Gallotannin (or tannic acid) is a naturally occurring compound that inhibits cell growth and activity of different DNA-polymerases, including telomerase. Gallotannin inhibits telomerase in vitro with a half maximal inhibitory concentration value of 130 nM, but it does not affect telomerase complex assembly and component levels in vivo. The inhibitory activity of gallotannin against telomerase provides an additional explanation for the anti-cancer activities of this compound.
Gallotannin (CAS 1401-55-4) is an inhibitor of NOS3 (eNOS) and a weak inhibitor of NOS2 (iNOS) and NOS1 (nNOS). This modulation of nitric oxide synthase isoforms has implications for both inflammation (via iNOS suppression) and vascular tone. Gallotannin has protective effects against hydrogen peroxide-induced oxidative stress and DNA damage.
The ability of gallotannin to suppress the transcription of inflammatory genes and reduce the expression of cytokines and chemokines is most likely via its antioxidant property. In cell and animal studies, the NF-κB (nuclear factor kappa B) signaling pathway has been identified as a major target: suppression of NF-κB activation reduces downstream production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β.
Gallotannins could be easily degraded by bacteria, fungi, and yeasts. Microorganisms present in the rumen and the distal portion of the monogastric intestine of the ruminants were involved in the hydrolysis of ester and depside bonds within gallotannin structures, releasing free gallic acid and related metabolites. Because of the binding with protein of gallotannins, the bioavailability of both the proteins and polyphenols would be reduced. Previous studies suggested that vegetable tannins possess a high binding affinity to proline-rich proteins.
Evidence level: Strong (in vitro and animal); preliminary in humans.
Gallotannin (GT), a polyphenolic compound, has shown various biological effects such as anti-oxidant, anti-inflammatory, antimicrobial, and antitumor effects. The antioxidant activity of gallotannins is among the best-documented properties of this class. Multiple in vitro assays (DPPH, FRAP, ORAC, ABTS) consistently show potent radical-scavenging capacity. Tannic acid demonstrated the most potent antioxidative activity (EC50 = 2.84 μM), with potency increasing proportionally to the number of galloyl moieties. As of current evidence, robust controlled clinical trial data in humans demonstrating measurable antioxidant outcomes from isolated gallotannin supplementation are lacking.
Evidence level: Preclinical only (in vitro and animal models); no approved clinical use and no completed human clinical trials reported in the peer-reviewed literature.
The polyphenolic hydrolyzable tannin, gallotannin (GT), also known as tannic acid, possesses interesting anticarcinogenic properties. Evidence from experimental studies suggests that GT is effective against multiple cancer types. Gallotannin has been shown to induce programmed cell death in a wide variety of cancers including colon, breast, prostate, and liver, among others. Apoptosis, cellular senescence, autophagy, and necrosis are the main mechanisms by which GT can suppress cancer progression. In addition, GT is a potent inhibitor of many proliferation pathways.
In the context of colorectal cancer, a preclinical study published in PubMed (PMID 34247563) reported that oral administration of GT suppressed the lung metastasis of metastatic CRC cells in an experimental mouse model. GT decreased the viability of metastatic CRC cell lines, including CT26, HCT116, and SW620, by inducing apoptosis through the activation of extrinsic and intrinsic pathways, cell cycle arrest through inactivation of the CDK2/cyclin A complex, and autophagic cell death through up-regulation of LC3B and p62 levels.
In the context of triple-negative breast cancer, a 2014 study at McGill University (PMC3962455) found that triple-negative breast cancer cells display higher levels of sensitivity to gallotannin. The loss of proliferative capacity in gallotannin-exposed cells is associated with slowed cell cycle progression and S phase arrest, dependent on Chk2 phosphorylation and further characterized by changes to proliferation-related genes, such as cyclin D1, as determined by Nanostring technology. Importantly, gallotannin administered orally or via intraperitoneal (IP) injections greatly reduced tumor outgrowth of triple-negative breast cells from mammary fat pads without signs of toxicity. These data strongly suggest that gallotannin represents a novel approach to treat triple-negative breast carcinomas.
Regarding telomerase inhibition as a broader anti-tumor mechanism: gallotannin inhibits telomerase in vitro with a half maximal inhibitory concentration value of 130 nM, but it does not affect telomerase complex assembly and component levels in vivo.
For glioblastoma multiforme (GBM), a study from PMC8708140 investigated gallotannin-enriched fraction from Quercus infectoria galls: the inhibitory effects exerted by the gallotannin fraction treatment on GBM cells were comparable to the effects of two clinically used chemo-drugs (Temozolomide and Tamoxifen), indicating its high efficiency in combating human cancer. This study pioneered the development of an optimized extraction procedure for enriched yield of the natural gallotannin metabolite from the galls of the QI medicinal plant with high antioxidant potential and inhibitory effects on human GBM cells.
For PGG specifically: three published in vivo preclinical cancer model studies with PGG support promising efficacy to selectively inhibit malignancy without host toxicity. Potential mechanisms include anti-angiogenesis and anti-proliferative actions through inhibition of DNA replicative synthesis. PGG acts on multiple molecular targets and signaling pathways associated with the hallmarks of cancer to inhibit growth, angiogenesis, and metastasis of several cancers.
Important limitation: All anti-cancer evidence for gallotannins as isolated compounds remains at the preclinical (cell culture and animal) level. No completed human clinical trials evaluating gallotannin as a cancer treatment have been identified in peer-reviewed literature.
Evidence level: In vitro and animal models (preclinical); no substantial human clinical trial evidence.
Gallotannins are phenolic natural products containing galloyl moieties connected to polyhydric alcohol cores, e.g., D-glucose. Some gallotannins are reported to have antidiabetic properties, such as α-glucosidase inhibitory activity.
Pentagalloyl glucose, a natural compound, demonstrated the highest α-glucosidase inhibitory activity (IC50 = 0.336 μM). Multiple C-glucosidic ellagitannins and galloylated glucoses were studied as potential α-glucosidase and α-amylase inhibitors. Most of the compounds were found to be moderate inhibitors of α-amylase, but potent inhibitors of α-glucosidase, showing low-micromolar IC50 values, far lower than that of the antidiabetic drug acarbose. This selectivity can be an advantage for their possible application as functional food ingredients with anti-diabetic properties because strong α-amylase inhibition generally causes undesired side effects.
Beyond enzyme inhibition, gallotannins act through multiple antidiabetic mechanisms: extensive research demonstrates that gallotannins specifically obstruct α-amylase and pancreatic lipase, enhance insulin sensitivity, modulate short-chain fatty acid production, alleviate oxidative stress, exhibit anti-inflammatory properties, and influence the gut microbiota, collectively contributing to their antidiabetic efficacy.
In the context of diabetic nephropathy, animal model studies (see ResearchGate ref 342385214) found that gallotannin ameliorates streptozotocin-induced diabetic nephropathy by preventing PARP activation, and that protection in poly (ADP-ribose) polymerase (PARP) cleavage signified the protective role of gallotannins in cell death signaling, portending gallotannins to be used as an alternative approach to ameliorate the development of streptozotocin-induced diabetic nephropathy.
Important limitation: Evidence is confined to cell-based assays and rodent models. Human trials on gallotannin for glycemic control are not yet established in the published literature.
Evidence level: In vitro; no substantial human clinical trial evidence.
Gallotannin inhibited microbial growth of both Gram-positive and Gram-negative pathogens through its antimicrobial activity. PGG has been shown to have anti-virus activities against HSV (herpes simplex virus), HIV, HBV, and HCV.
In more specific antiviral in vitro work, PGG was tested for anti-HSV activity in an in vitro FL cells culture model. The data showed that PGG had an anti-HSV ED50 of 12 μM whereas its IC50 to host cells was 117 μM. Structure-activity relationship studies indicated that anti-virus activity was positively correlated with the numbers of phenolic groups. The cytotoxicities to host cells of tannins paralleled their antiviral activities, which suggested that the activities could be based on the interaction with the proteins of FL cell surfaces.
PGG has been widely recognized to possess antimicrobial, anti-viral (including in the treatment with coronavirus disease [COVID-19]), anti-diabetic, anti-inflammatory, and anti-tumor properties. The COVID-19 angle is based on early mechanistic and in vitro work and should not be construed as clinical evidence of efficacy.
Evidence level: Animal models; no substantial human clinical trial evidence.
To investigate the toxicity, protective effects, and action mechanism of gallotannin-enriched extracts isolated from Galla Rhois (GEGR) against carbon tetrachloride (CCl4)-induced hepatotoxicity in ICR mice, alterations in serum biochemical indicators, histopathological structure, antioxidative status, hepatic apoptosis-related proteins, and liver fibrosis-regulating factors were measured. The GEGR/CCl4-treated group showed decreased levels of three serum marker enzymes (ALP, AST, and ALT) representing liver toxicity. Necrotic area indicating hepatic cell death was significantly inhibited, while malondialdehyde (MDA) concentration and superoxide dismutase (SOD) expression were dramatically recovered in the GEGR preadministrated group.
For PGG specifically, it has been reported that PGG ameliorates high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) and preserves the regulation of genes associated with lipid balance in mice. Furthermore, the combination of PGG and metformin almost completely reverses the pathophysiological changes in NAFLD in mice by inducing the expression of glycine N-methyltransferase. PGG also exhibits hepatoprotective properties by activating Nrf2 nuclear translocation in a manner dependent on extracellular signal-regulated kinases, leading to the induction of HO-1 expression.
Evidence level: Animal models; traditional use in humans, but no controlled human clinical trials identified.
Several natural products containing tannins are used as traditional medicines for treatment of constipation; however, their pharmacological mechanism is not well understood. Paradoxically, gallotannin-rich preparations (Galla Rhois) are recorded as traditional treatments for both diarrhea (astringent effect) and constipation (laxative effects at certain doses or preparations), illustrating a dose- and preparation-dependent response.
A 2016 study in rodents (PMC5019396) investigated laxative properties: GEGR has traditionally been used for treatment of diarrhea, several skin diseases, seminal emissions, excessive sweating, abscess, bleeding, and chronic cough without any recorded toxicity. The use of GR to treat diarrhea has only been investigated based on antibiotics activity in Eimeria tenella-infected chickens and highly infectious post-weaning piglets, regardless of key role as laxatives for the regulation of bowel movement.
Evidence level: In vitro and invertebrate model (Drosophila); no human clinical trial data.
The plant-derived tannin 1,2,3,4,6-Penta-O-Galloyl-β-D-Glucose (β-PGG) displays potent antioxidant, anti-inflammatory, and neuroprotective properties in vitro, but in vivo evidence is limited. A study assessed the dose-dependent efficacy and therapeutic mechanisms of β-PGG in mitigating age-dependent mobility deficits in a Drosophila melanogaster model of AD. A fruit fly line overexpressing the human amyloid precursor protein (hAPP) and β-site APP-cleaving enzyme (hBACE) in neurons was used as the AD model. Newly eclosed flies were supplemented with 0, 5, or 10 μM β-PGG and locomotion was assessed at 7, 14, 21, and 30 days via a negative geotaxis assay.
Among the various antioxidants, tannin and tannin-related plant extracts have received great attention, since recent studies have demonstrated the tight correlation between antioxidant treatments and symptomatic relief of AD symptoms. In vitro work has shown that gallotannins can inhibit aggregation of amyloid-β peptides, a hallmark of Alzheimer's pathology. However, all such evidence remains preclinical.
Evidence level: In vitro and animal models; no controlled human trial data.
The ability of gallotannin to suppress the transcription of inflammatory genes and reduce the expression of cytokines and chemokines is most likely via its antioxidant property. Gallotannins and their metabolites have been reviewed as contributors to the anti-inflammatory effect of food products and medicinal plants, acting through inhibition of NF-κB, suppression of pro-inflammatory enzyme activities (COX-2, iNOS), and modulation of cytokine profiles in experimental models. This evidence derives predominantly from cell-based and animal studies.
Gallotannins and gallotannin-rich extracts have been reported to possess many useful bioactivities, including antioxidant, antibacterial, antiproliferative, cardiovascular protective, hepatoprotective, and anti-diabetic activities. The body systems and health areas with which gallotannin research has been associated include:
There are no established human therapeutic doses for isolated gallotannin (as gallotannin or PGG) based on completed clinical trials. The following dosages are reported only in the preclinical studies cited in this article:
In the context of gallotannins consumed naturally through the diet (e.g., from pomegranate, mango, sumac-spiced foods, tea, and wine), intakes are highly variable and have not been standardized in dietary reference values. No governmental health body (NIH ODS, EFSA, WHO) has established a recommended daily intake or tolerable upper intake level for gallotannin as a distinct dietary supplement ingredient.
The body and organ weight, clinical phenotypes, urine parameters, and mice mortality did not differ among GEGR-treated groups and the vehicle-treated group. Furthermore, no significant increase was observed in alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), and serum creatinine (Cr) in the GEGR-treated group relative to the vehicle-treated group. Moreover, the specific pathological features induced by most toxic compounds such as CCl4 were not observed upon liver and kidney histological analysis. Overall, the results suggest that GEGR does not induce any specific toxicity in liver and kidney organs of ICR mice at doses of 1,000 mg/kg body weight/day, indicating that this is the no observed adverse effect level (NOAEL).
Damage induced by hydrogen peroxide or Fe2+ on DNA would be alleviated considerably by gallotannins. Based on these results, it could be concluded that synthetic gallotannins represent non-toxic agents, implying the potential biomedical applications of gallotannins.
Dietary tannin reduces protein digestibility and nitrogen availability, presumably related to its ability to bind substrates (protein, starch) and/or inhibit digestive enzymes (pectinase, amylase, lipase, protease, and β-galactosidase). This property — central to the potential metabolic benefits of gallotannin — simultaneously means that high intakes could theoretically reduce the bioavailability of dietary proteins and certain micronutrients. This is an anti-nutritional consideration of relevance at high supplemental intakes, especially in populations with marginal protein status.
It is accepted that tannins reduce iron availability before absorption through the formation of insoluble antinutritional-mineral complexes, and reported exacerbation of iron-deficiency anemia (IDA) by foods high in phytates or tannins is common. Single-meal studies have confirmed iron bioavailability inhibition with tannin consumption.
However, the picture is more nuanced with hydrolyzable tannins (the class to which gallotannins belong): hydrolyzable tannins have different affinities than condensed tannins when binding to proline-rich proteins (PRPs). In vivo, hepatic iron stores and non-heme iron absorption are not significantly affected by tannin consumption, and PRP expression may increase non-heme iron bioavailability with tannin consumption. Hydrolyzable tannins are not representative of tannin impact on non-heme iron bioavailability in food tannins because of their unique structural properties and PRP affinities. With tannin consumption, PRP production is increased, and may be an initial line of defense against tannin–non-heme iron chelation in vivo.
The practical implication is that iron absorption inhibition by gallotannins specifically may be less clinically significant than that attributed to condensed (grape-seed) tannins, though individuals with iron deficiency anemia or high iron requirements should be aware of any potential interaction.
Because of the binding with protein of gallotannins, bioavailability of both the proteins and polyphenols would be reduced. The high molecular weight and polarity of gallotannins such as tannic acid limit their intact absorption across the intestinal epithelium. PGG is considered more bioavailable among gallotannins; PGG is described as a highly bioavailable polyphenolic compound, which is one of the most potent antioxidants in the tannins group. However, gut microbiota-mediated hydrolysis to smaller phenolic metabolites (primarily gallic acid and pyrogallol) substantially alters the pharmacokinetic profile of ingested gallotannins, and the biological activity of the intact molecule versus its metabolites remains an important open research question.
The protein-binding and metal-chelating properties of gallotannins suggest a theoretical potential for interaction with orally co-administered medications, particularly alkaloid-based drugs (with which tannins readily form insoluble precipitates), iron supplements, and medications binding to serum proteins. These interactions are based on physicochemical principles well-established in the broader tannin literature. No specific human clinical interaction studies with gallotannin as an isolated compound have been published in the peer-reviewed sources identified for this article.
The existing safety data are based entirely on animal studies. No controlled clinical safety data in pregnant or lactating women, children, or individuals with hepatic or renal impairment are available for isolated gallotannin supplementation. The NOAEL established in mice (1,000 mg/kg body weight/day in ICR mice) cannot be directly extrapolated to human dosing without interspecies conversion.
The research on gallotannins has progressed substantially at the biochemical and preclinical level. Improvement of bioavailability, chemical modification of the structure, and accurate determination of new gallotannins were pointed out as orientations for the future. PGG has a broad range of biological activities, specifically anticancer activities, and numerous molecular targets. Despite multiple studies available on the pharmacological action of PGG, the molecular mechanisms underlying the anticancer effects of PGG are unclear.
Despite study for centuries, there are still many confused conclusions and unresolved contradictions waiting to be figured out. For instance, structural definition and scientific classification are still ambiguous. Also, functional activities of gallotannins are multifarious.
Key evidence gaps include: (1) absence of Phase I/II human clinical trials for any indication; (2) incomplete pharmacokinetic profiling in humans; (3) unknown safe supplemental dose range in humans; (4) limited understanding of which biological activities are attributable to the intact gallotannin molecule versus its hydrolysis products; (5) no established biomarkers of exposure or effect for human supplementation studies.
Health conditions that Gallotannin may help support.
Body systems that Gallotannin may help support.
Go back